Evaluation of immature monocyte-derived dendritic cells generated from patients with colorectal cancer

• Authors: Ryszard Maciejewski , Sebastian Radej , Jacek Furmaga , Andrzej Chrościcki , Sławomir Rudzki , Jacek Roliński , Grzegorz Wallner
• Languages of publication: EN

Abstracts

EN

Dendritic cells are heterogeneous population of the leukocytes and most potent APC in activation of naive T lymphocytes. Therefore the DCs generated in vitro are under research for their application in anti-tumor immunotherapy. The aim of the study was generation of the immature dendritic cells from peripheral blood monocytes collected from colorectal cancer patients and comparison of their ability to endocytosis, cytokine production and immunophenotype to DCs generated from healthy donors. Material and methods. 16 adenocarcinoma stage II patients were included in the study. Dendritic cells were generated in the presence of rhGM-CSF and IL-4. PBMC were isolated from the blood of patients and 16 healthy donors - control group. Immunophenotype, ability of endocytosis of Dextran- FITC as well as intracellular IL-12 expression of the generated dendritic cells was measured using flow cytometry. The cytokines (IL-6, IL-10, IL-12p70, IFN-γ) concentration in the supernatants of DCs culture was measured by ELISA. Results. The percentage of the immature dendritic cells and expression of CD206 and CD209 antigens was significantly higher in patients group (p <0.05 and p <0.001 respectively). Significantly (p <0.001) higher expression of the antigens which initiate the Th2 immune response (CD80-/CD86 + and B7-H2 + / CD209 +) was in the patients group. There were no differences in endocytosis ability and the cytokines (IL-6, IL-10, IL-12p70, IFN-γ) concentration between investigated groups. Conclusions. High immature markers expression on the generated dendritic cells together with identical endocytosis ability in patients group is advantageous in antitumor autologous cells immunotherapy planning. However there is one troubling fact - high expression of markers, which may induce tolerance to particular antigen. It seems to be more reasonable to use the autologous DCs in the antitumor immunotherapy, especially due to the incompatibility in allogenic cells in the context of HLA complex.

Keywords

EN

dendritic cells; colon cancer; immunotherapy

• Publisher: De Gruyter Open
• Journal: Polish Journal of Surgery
• Year: 2013
• Volume: 85
• Issue: 12
• Pages: 714-720

Dates

published

1 - 12 - 2013

online

25 - 01 - 2014

Contributors

author

Ryszard Maciejewski

• Laboratory of Biostructure, Human Anatomy Department, Medical University in Lublin

author

Sebastian Radej

• Laboratory of Biostructure, Human Anatomy Department, Medical University in Lublin

author

Jacek Furmaga

• Department of General and Transplant Surgery and Nutritional Treatment, Medical University in Lublin

author

Andrzej Chrościcki

• Department of General and Oncological Surgery, District Specialist Hospital in Lublin

author

Sławomir Rudzki

• Department of General and Transplant Surgery and Nutritional Treatment, Medical University in Lublin

author

Jacek Roliński

• Department of Clinical Immunology, Medical University in Lublin

author

Grzegorz Wallner

• Department of General and Gastroenterological Surgery and Surgical Oncology of the Alimentary Tract, Medical University in Lublin

References

• 1. W ojciechowska U, Didkowska J, Zatoński W: Nowotwory złośliwe w Polsce w 2009 roku. Centrum Onkologii-Instytutu im. Marii Skłodowskiej-Curie.Warszawa 2011.
• 2. D idkowska U, Wojciechowska J, Zatoński W: Prognozy zachorowalności i umieralności na wybrane nowotwory złośliwe w Polsce do 2025 roku.Centrum Onkologii-Instytutu im. Marii Skłodowskiej- Curie. Warszawa 2009.
• 3. F earon ER : Molecular Genetics of Colorectal Cancer. Annual Review of Pathology. Mechanisms of Disease 2011; Vol. 6 479-507.
• 4. Gonciarz M, Pierzchalski P, Lorens K et al.: Genetic aspects of colorectal carcinogenesis. Wiad Lek 2004; 57: 74-79.
• 5. T erzić J, Grivennikov S, Karin E et al.: Inflammation and colon cancer. Gastroenterology 2010; 138: 2101-14.
• 6. C ampos F, Logullo Waitzberg A, Kiss D et al.: Diet and colorectal cancer: current evidence for etiology and prevention. Nutr Hosp 2005; 20: 18-25.
• 7. N oah TK, Shroyer NF : Notch in the Intestine: Regulation of Homeostasis and Pathogenesis. Ann Rev Physiol 2013; 75: 263-88.
• 8. S chreiber RD , Old LJ, Smyth MJ: Cancerimmunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 2011; 6024: 1565-70.[WoS]
• 9. Pardol D: Does the immune system see tumors as foreign or self? Annu Rev Immunol 2003; 21: 807-39.[Crossref]
• 10. M a Y, Shurin GV, Peiyuan Z et al.: Dendritic cells in the cancer microenvironment. J Cancer 2013; 4: 36-44.[PubMed]
• 11. S teinman MR : Decisions About Dendritic Cells: Past, Present, and Future. Annu Rev Immunol 2012; 30: 1-22.[WoS]
• 12. D illman RO , Cornforth AN , Depriest Cet al.: Tumor stem cell antigens as consolidative active specific immunotherapy: a randomized phase II trial of dendritic cells versus tumor cells in patients with metastatic melanoma. J Immunother 2012; 35: 641-49.[WoS]
• 13. E l Ansary M, Mogawer S, Elhamid SA et al.: Immunotherapy by autologous dendritic cell vaccine in patients with advanced HCC. J Cancer Res Clin Oncol 2013; 139: 39-48.
• 14. C onti L, Gessani S: GM-CSF in the generation of dendritic cells from human blood monocyte precursors: recent advances. Immunobiol 2008; 213: 859-70.
• 15. Conti L, Cardone M, Varano B et al.: Role of the cytokine environment and cytokine receptor expression on the generation of functionally distinct dendritic cells from human monocytes. Eur J Immunol 2008; 38: 750-62.[WoS][Crossref][PubMed]
• 16. Kim JH, Lee Y, Bae YS et al.: Phase I/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma. Clin Immunol 2007; 125: 257-67.[WoS]
• 17. M atsumoto A, Haraguchi K, Takahashi T et al.: Immunotherapy against metastatic renal cell carcinoma with mature dendritic cells. Int J Urol 2007; 14: 277-83.
• 18. Geijtenbeek TB, van Vliet SJ, Engering A et al.: Self- and nonself-recognition by C-type lectins on dendritic cells. Annu Rev Immunol 2004; 22: 33-54.[Crossref]
• 19. Von Euw EM , Barrio MM , Furman D et al.: A phase I clinical study of vaccination of melanoma patients with dendritic cells loaded with allogeneic apoptotic/necrotic melanoma cells. Analysis of toxicity and immune response to the vaccine and of IL-10 -1082 promoter genotype as predictor of disease progression. J Transl Med 2008; 6: 6.[WoS]
• 20. Giordano D, Magaletti DM , Clark EA et al.: Cyclic nucleotides promote monocyte differentiation toward a DC-SIGN+ (CD209) intermediate cell and impair differentiation into dendritic cells. J Immunol 2003; 171: 6421-30.
• 21. Kato M, Neil TK, Fearnley DB et al.: Expression of multilectin receptors and comparative FITCdextran uptake by human dendritic cells. Int Immunol 2000; 12: 1511-19.[Crossref]
• 22. D ilioglou S, Cruse JM, Lewis RE : Function of CD80 and CD86 on monocyte- and stem cell-derived dendritic cells. Exp Mol Pathol 2003; 75: 217-27.
• 23. W ang S, Zhu G, Chapoval AI et al.: Costimulation of T cells by B7-H2, a B7-like molecule that binds ICOS. Blood 2000; 96: 2808-13.
• 24. L ee H, Kim JH, Yang SY et al.: Peripheral blood gene expression of B7 and CD28 family members associated with tumor progression and microscopic lymphovascular invasion in colon cancer patients. J Cancer Res Clin Oncol 2010; 136: 1445-52.[WoS]
• 25. Banchereau J, Briere F, Caux C et al.: Immunobiology of Dendritic Cells. Annu Rev Immunol 2000; 18: 767-811.[PubMed][Crossref]
• 26. Bonehill A, Heirman C, Tuyaerts Set al.: Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II molecules. J Immunol 2004; 172: 6649-57.
• 27. F ooksman DR , Vardhana S, Vasiliver-Shamis G et al. Functional anatomy of T Cell activation and synapse formation: Annu Rev Immunol 2010; 28: 79-105.[PubMed]
• 28. Ghanekar SA , Bhatia S, Ruitenberg JJ et al.: Phenotype and in vitro function of mature MDDC generated from cryopreserved PBMC of cancer patients are equivalent to those from healthy donors. J Immune Based Ther Vaccines 2007; 5: 7.

Identifiers

DOI

10.2478/pjs-2013-0109